Repros Therapeutics : US76028H1005 / RPRX - NASDAQ

Ladenburg Thalmann - Repros Therapeutics "buy"

16:58 20.08.10
http://www.ariva.de/news/...erapeutics-buy-Ladenburg-Thalmann-3509779

Rating-Update:

New York (aktiencheck.de AG) - Die Analysten von Ladenburg Thalmann stufen die Aktie von Repros Therapeutics (Profil) von "neutral" auf "buy" hoch. Das Kursziel sehe man bei 1,50 USD. (20.08.2010/ac/a/u)

**************************************************

18.08.2010 12:31
http://www.finanznachrichten.de/...iii-protocols-for-androxal-004.htm
                    §
Repros Requests Type B Meeting with FDA to Discuss Phase III Protocols for Androxal®

Larry I. Lipshultz, MD Agrees to Serve as Lead Investigator for Phase III Program

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal® in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

Larry I. Lipshultz, MD, Baylor College of Medicine, Professor, Scott Department of Urology, Lester and Sue Smith Chair in Reproductive Medicine, and Past President, American Society for Reproductive Medicine has agreed to serve as Lead Investigator for the Company's Phase III program and will help Repros in preparing the pivotal protocols. The studies are being designed to show that only Androxal normalizes both testosterone and sperm concentrations as compared to topical testosterone or placebo. In a small pilot study previously conducted by Repros, only Androxal resulted in normalization of both testosterone and sperm counts in a majority of subjects. In this population of men that previously used a topical testosterone, no men on testosterone or placebo exhibited normal concentrations for both measures. Per FDA recommendation, benefit will be determined by "normalization of serum testosterone levels while preserving fertility."

Dr. Lipshultz commented, "In an era when increasingly more men are turning to testosterone replacement therapy for treatment of their low testosterone, it is important to many of these men to be able to maintain normal sperm production (spermatogenesis). Androxal has the potential to play an important role in helping to maintain normal sperm production in those men for whom testosterone replacement therapy is their best treatment and for whom the maintenance of normal spermatogenesis is equally as important."

**************************************************

13.08.2010 21:58
http://www.finanznachrichten.de/...-price-listing-requirement-004.htm

Nasdaq Grants Repros Extension until October 31, 2010 to Meet Minimum Bid Price Listing Requirement

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that Nasdaq has granted the Company until October 31, 2010 to meet the minimum bid price requirement of the Nasdaq Capital Market. Listing Rule 5550(a)(2) requires the Company to maintain a minimum bid price of $1.00 for a minimum of ten consecutive trading days. At the Company's annual stockholders' meeting held on May 17, 2010, the stockholders approved a proposal to grant the Company's board of directors the authority to effect a reverse split of its common stock within one year of such annual meeting on a basis not to exceed one share of common stock for up to five shares of common stock outstanding, if necessary, in the sole discretion of the Company's board of directors, for purposes of maintaining its listing on the Nasdaq Capital Market.

In accordance with the decision of the Nasdaq Hearings Panel, Repros has to meet all of the continued listing requirements of the Nasdaq Capital Market by October 31, 2010, or its securities will, in all likelihood, be delisted from The Nasdaq Stock Market promptly following such date.

**************************************************

HOMEPAGE: www.reprosrx.com/